Clinical Trial Details
| Trial ID: | L4579 |
| Source ID: | NCT00288236 |
| Associated Drug: | Rimonabant (Sr141716) |
| Title: | Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Patients(ARPEGGIO) |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Type 2 Diabetes Mellitus |
| Interventions: | DRUG: Rimonabant (SR141716)|DRUG: Placebo |
| Outcome Measures: | Primary: Absolute change in HbA1C from baseline to Week 48 | Secondary: Fasting glucose, total daily insulin dose, body weight, waist circumference, HDL-cholesterol, triglycerides, safety (physical examination, vital signs, laboratory tests, adverse events). |
| Sponsor/Collaborators: | Sponsor: Sanofi |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE3 |
| Enrollment: | 368 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT |
| Start Date: | 2006-01 |
| Completion Date: | 2007-07 |
| Results First Posted: | |
| Last Update Posted: | 2009-04-07 |
| Locations: | Sanofi-Aventis, Bridgewater, New Jersey, 08807, United States|Sanofi-Aventis, Buenos Aires, Argentina|Sanofi-Aventis, Lane Cove, Australia|Sanofi-Aventis, Laval, Canada|Sanofi-Aventis, Providencia, Chile|Sanofi-Aventis, Paris, France|Sanofi-Aventis, Berlin, Germany|Sanofi-Aventis, Milano, Italy|Sanofi-Aventis, Gouda, Netherlands|Sanofi-Aventis, Moscow, Russian Federation|Sanofi-Aventis, Midrand, South Africa|Sanofi-Aventis, Guildford, United Kingdom |
| URL: | https://clinicaltrials.gov/show/NCT00288236 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|